Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 3/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | MLYCD | O95822 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | CDC25B | P30305 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3272215 | 0.80 | ERN1 (0.50) | ERN1MCL1ALDH1A1HPGD | |
| SCHEMBL4455035 | 0.78 | ALDH1A1 (0.59) | ALDH1A1MAPTHPGDMLYCD | |
| SCHEMBL28371598 | 0.77 | ALDH1A1 (0.57) | ERN1MCL1ALDH1A1MAPTHPGD | |
| SCHEMBL3267828 | 0.76 | MEN1 (0.48) | ERN1ALDH1A1MAPTHPGDCYP19A1 | |
| SCHEMBL3299767 | 0.74 | ALDH1A1 (0.52) | ALDH1A1MAPTHPGDCLK1DYRK1A | |
| SCHEMBL1515914 | 0.74 | CES2 (0.53) | ALDH1A1MAPTHPGDMLYCD | |
| SCHEMBL3269434 | 0.73 | NCEH1 (0.48) | ERN1ALDH1A1 | |
| SCHEMBL23708187 | 0.72 | ERN1 (0.48) | ERN1MLYCD | |
| SCHEMBL3269014 | 0.72 | ERN1 (0.55) | ERN1MCL1ALDH1A1MAPTHPGD | |
| SCHEMBL18678765 | 0.71 | LMNA (0.40) | ERN1ALDH1A1MAPTHPGDMLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1914229-B1 | NOVEL CERCOSPORAMIDE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-20090036492-A1 | Novel Cercosporamide Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1914229-A1 | NOVEL CERCOSPORAMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036492-A1 | Novel Cercosporamide Derivative | GPR119, CBR3, SLC5A2 | ERN1 337/4885MCL1 3227/4885ALDH1A1 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.